- Chief executive Jean-Pierre Garnier said it had been a "difficult year"
- Company absorbed over Â£1.5bn of lost sales to generics but still managed to grow the business.
- 2005 will also be an important year in terms of research and development pipeline progress.
- Firm discontinued development of an experimental treatment for obesity, known as '771, after disappointing clinical trial results.
